Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
746 JPY | 0.00% | -1.45% | -2.10% |
Business Summary
Number of employees: 21
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Regenerative Medicine
70.2
%
| 120 | 32.0 % | 43 | 70.2 % | -64.22% |
Device
29.1
%
| 235 | 62.6 % | 18 | 29.1 % | -92.42% |
Drug Discovery Support
0.7
%
| 20 | 5.3 % | 0 | 0.7 % | -97.88% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
98.6
%
| 332 | 88.7 % | 60 | 98.6 % | -81.85% |
United States
1.4
%
| 2 | 0.5 % | 1 | 1.4 % | -55.92% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shizuka Akieda
CEO | Chief Executive Officer | - | - |
Masahiro Sanjo
DFI | Director of Finance/CFO | - | - |
Director/Board Member | - | 14-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Takuo Hirose
BRD | Director/Board Member | 53 | - |
Kunihiko Suzuki
BRD | Director/Board Member | 65 | - |
Shizuka Akieda
CEO | Chief Executive Officer | - | - |
Masahiro Sanjo
DFI | Director of Finance/CFO | - | - |
Director/Board Member | - | - | |
Yoichi oda
BRD | Director/Board Member | - | - |
Kazuya Oda
BRD | Director/Board Member | - | - |
Director/Board Member | - | 14-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 8,130,800 | 5,171,900 ( 63.61 %) | 0 | 63.61 % |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-2.10% | 37.72M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- 4892 Stock
- Company Cyfuse Biomedical K.K.